The goal of this experimental research project is to expand the scope of our existing IP to include specific, measured evidence of critical parameters, i.e. ‘biomarkers’, for ‘closed-loop’ control of fsCT-DBS protocols. Daedalus funding will provide WCM with the sole rights to these new inventions and strengthen our existing IP portfolio potentially broadening the future applications of our new fsCT-DBS system to emerging indications in the rapidly expanding neuromodulation market.